Nxera Pharma Co.,Ltd.
Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy
Filed with TSE ·
Watch Nxera Pharma's latest callNxera Pharma (Tokyo:4565) Q2 2026 Earnings Call · Replay · Aug 7Read the transcript of Nxera Pharma (Tokyo:4565) Q2 2026 Earnings Call6ix is reading this filing.
View original source (TDnet)Nxera Pharma Co., Ltd. on 6ix
Story so far
- Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
- Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
- Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Earlier from Nxera Pharma
- Introduction of the Executive Officer Performance Stock Option Plan and Issuance of Stock Acquisition Rights Under the Plan
- Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ Across Eight Asia-Pacific Markets
- Nxera Announces Successful Resolution of miniG Patent Infringement Action
- Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
- Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Follow Nxera Pharma into a list and get an email when it puts out news.
Follow Nxera Pharma